Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Neohesperidine Dc
2. Neohesperidine Dihydrochalcone
1. 20702-77-6
2. Nhdc
3. Neohesperidin Dc
4. Neohesperidin Dhc
5. Neohesperidine Dihydrochalcone
6. Neohesperidine
7. Nci-c60764
8. Neohesperidin-dihydrochalcone
9. Neosperidin Dihydrochalcone
10. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
11. Neohesperidin Dihydrochalone
12. Chebi:83535
13. 3x476d83qv
14. 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
15. 1-propanone, 1-[4-[[2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2,6-dihydroxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)-
16. Citrosa
17. Neohesperidine Dc
18. 1-(4-(((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-2-yl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
19. 1-propanone, 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
20. Ccris 4848
21. Einecs 243-978-6
22. Unii-3x476d83qv
23. Neohesperidin Dihydrochalcone (nhdc)
24. Neosperidin-dihydrochalcone
25. Dsstox_cid_5706
26. Dsstox_rid_77887
27. Dsstox_gsid_25706
28. 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
29. 1-propanone, 1-(4-((2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-me
30. 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl) 2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
31. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-, Beta-d-
32. Schembl909958
33. Chembl1159645
34. Dtxsid3025706
35. Fema No. 3811
36. Itvgxxminpyuhd-cuvhlrmhsa-
37. Hms3884h13
38. Hy-n0154
39. Zinc4175639
40. Tox21_200303
41. S2331
42. 1-(4-((2-o-[6-deoxy-&alpha
43. Akos015895239
44. Ccg-270237
45. Cs-6419
46. Ncgc00091109-01
47. Ncgc00091109-02
48. Ncgc00091109-04
49. Ncgc00257857-01
50. 1-(4-((2-o-[6-deoxy-alpha-l-mannopyranosyl]-beta-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-[3-hydroxy-4-methoxyphenyl]-1-propanone
51. 3,5-dihydroxy-4-[3-(3-hydroxy-4-methoxyphenyl)propanoyl]phenyl 2-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside
52. Ac-34860
53. As-15190
54. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-, .beta.-d-
55. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl-2-o-(6-deoxy-alpha-l-mannopyranosyl)-, Beta-d-
56. Neohesperidin Dihydrochalcone [mi]
57. Neohesperidin Dihydrochalcone, >=96%, Fg
58. Neohesperidin Dihydrochalone [fhfi]
59. Cas-20702-77-6
60. Neohesperidin Dihydrochalcone [inci]
61. Neohesperidine Dihydrochalcone [fcc]
62. N0675
63. Neohesperidin Dihydrochalcone [usp-rs]
64. Neohesperidin Dihydrochalcone, >=95% (hplc)
65. Neohesperidine Dihydrochalcone [usp-rs]
66. Neohesperidin Dihydrochalcone, Analytical Standard
67. 702n776
68. A814825
69. Q424595
70. Sr-01000883756
71. Neohesperidin-dihydrochalcone [ep Monograph]
72. Q-201457
73. Sr-01000883756-1
74. Brd-k61032563-001-02-9
75. Hesperetin Dihydrochalcone-4'-.beta.-neohesperidoside
76. Neohesperidin Dihydrochalcone, European Pharmacopoeia (ep) Reference Standard
77. Neohesperidin Dihydrochalcone, United States Pharmacopeia (usp) Reference Standard
78. 1-(4-((2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-dihydrochalcone Glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
79. 1-(4-((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)tetrahydro-2h-pyran-2-yloxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)propan-1-one
80. 1-[4-[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-2-[(2r,3r,4s,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]oxy-tetrahydropyran-3-yl]oxy-2,6-dihydroxy-phenyl]-3-(3-hydroxy-4-methoxy-phenyl)propan-1-one
81. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5
82. 1-[4-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-2,6-dihydroxy-phenyl]-3-(3-hydroxy-4-methoxy-phenyl)propan-1-one
83. 1-propanone, 1-(4-((2-o-(6-deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,6-dihydroxyphenyl)-3-(3-hydroxy-4-methoxyphenyl)-
84. Glucopyranoside, 3,5-dihydroxy-4-(3-hydroxy-4-methoxyhydrocinnamoyl)phenyl 2-o-.alpha.-l-rhamnopyranosyl-
| Molecular Weight | 612.6 g/mol |
|---|---|
| Molecular Formula | C28H36O15 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 10 |
| Exact Mass | 612.20542044 g/mol |
| Monoisotopic Mass | 612.20542044 g/mol |
| Topological Polar Surface Area | 245 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 882 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Neohesperidin Dihydrochalcone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Neohesperidin Dihydrochalcone, including repackagers and relabelers. The FDA regulates Neohesperidin Dihydrochalcone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Neohesperidin Dihydrochalcone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Neohesperidin Dihydrochalcone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Neohesperidin Dihydrochalcone supplier is an individual or a company that provides Neohesperidin Dihydrochalcone active pharmaceutical ingredient (API) or Neohesperidin Dihydrochalcone finished formulations upon request. The Neohesperidin Dihydrochalcone suppliers may include Neohesperidin Dihydrochalcone API manufacturers, exporters, distributors and traders.
click here to find a list of Neohesperidin Dihydrochalcone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Neohesperidin Dihydrochalcone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Neohesperidin Dihydrochalcone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Neohesperidin Dihydrochalcone GMP manufacturer or Neohesperidin Dihydrochalcone GMP API supplier for your needs.
A Neohesperidin Dihydrochalcone CoA (Certificate of Analysis) is a formal document that attests to Neohesperidin Dihydrochalcone's compliance with Neohesperidin Dihydrochalcone specifications and serves as a tool for batch-level quality control.
Neohesperidin Dihydrochalcone CoA mostly includes findings from lab analyses of a specific batch. For each Neohesperidin Dihydrochalcone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Neohesperidin Dihydrochalcone may be tested according to a variety of international standards, such as European Pharmacopoeia (Neohesperidin Dihydrochalcone EP), Neohesperidin Dihydrochalcone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Neohesperidin Dihydrochalcone USP).
LOOKING FOR A SUPPLIER?
